Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study (Q37809370)

23 August 2017

Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study (English)

1 reference

23 August 2017

endometrial carcinoma

1 reference

1 reference

2

0 references

author name string

Allan L Covens

1

1 reference

23 August 2017

Deborah Gersell

3

1 reference

23 August 2017

Christopher V Lutman

4

1 reference

23 August 2017

Albert Bonebrake

5

1 reference

23 August 2017

Yi-Chun Lee

6

1 reference

23 August 2017

language of work or name

English

0 references

publication date

13 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

120

1 reference

23 August 2017

185-188

1 reference

23 August 2017

2

1 reference

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

A Survey of Exact Inference for Contingency Tables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Optimal flexible designs in phase II clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Fulvestrant: a further treatment option for patients with metastatic uterine cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.10.015

10.1016/J.YGYNO.2010.10.015

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference